2023 French recommendations for diagnosing and managing prepatellar and olecranon septic bursitis.

Sophie Godot, Carine Salliot, Pascal Guggenbuhl, Arthur Vrignaud, Christine Voquer, Raphaèle Seror, Eric Senneville, Jean-Maxime Piot, Denis Mulleman, Christian Lormeau, Thibaut Lecointe, Céline Hoffmann, Christelle Darrieutort-Laffite, Maël Faudemer, René-Marc Flipo, Emilie Ducourau Barbary, Pascal Coquerelle, Marion Couderc, Pascal Chazerain, Géraldine Bart, Fréderic Banal, Florence Aïm, Guillaume Coiffier

Journal: Joint bone spine 2024;91(2):105664

PMID: 37995861

Full Text on Elsevier Science View on PubMed

Abstract

Septic bursitis (SB) is a common condition accounting for one third of all cases of inflammatory bursitis. It is often related to professional activities. Management is heterogeneous and either ambulatory or hospital-based, with no recommendations available. This article presents recommendations for managing patients with septic bursitis gathered by 18 rheumatologists from the French Society for Rheumatology work group on bone and joint infections, 1 infectious diseases specialist, 2 orthopedic surgeons, 1 general practitioner and 1 emergency physician. This group used a literature review and expert opinions to establish 3 general principles and 11 recommendations for managing olecranon and prepatellar SB. The French Health authority (Haute Autorité de santé [HAS]) methodology was used for these recommendations. Designed for rheumatologists, general practitioners, emergency physicians and orthopedic surgeons, they focus on the use of biological tests and imaging in both outpatient and inpatient management. Antibiotic treatment options (drugs and duration) are proposed for both treatment modalities. Finally, surgical indications, non-drug treatments and prevention are covered by specific recommendations.

Address: Rheumatology Department, CHU de Nantes, Nantes, France; Nantes Université, Oniris, CHU de Nantes, Inserm, Regenerative Medicine and Skeleton, RMeS, UMR 1229, 44000 Nantes, France.; Rheumatology Department, Dinan Hospital, Dinan, France.; Orthopedic Unit and Osteoarticular Reference Center, GH Diaconesses Croix Saint-Simon, Paris, France.; Department of Rheumatology, Centre Hospitalier Universitaire Amiens Picardie, 80054 Amiens, France.; Internal Medicine and Rheumatology department, Percy Army Training Hospital, Clamart, France.; Rheumatology Department, Groupe Hospitalier Diaconnesses Croix Saint-Simon, 75020 Paris, France.; Rheumatology Department, CHU Gabriel-Montpied, Clermont-Ferrand, France; Inserm/Imost, UMR 1240, Clermont-Ferrand, France.; Rheumatology Department, Béthune Hospital, Béthune, France.; Medicine Department, Oreliance Health Center, Saran, France.; Department of Rheumatology, CHU de Lille, Université de Lille, 59000 Lille, France.; Rheumatology Department, CHU Saint-Antoine, 75012 Paris, France.; Emergency Department, Groupe Hospitalier Diaconnesses Croix Saint-Simon, 75020 Paris, France.; Orthopedic surgery Department, CHU d'Orléans, Orléans University, 45067 Orléans, France.; Rheumatology Department, Niort Hospital, Niort, France.; EA6295 Nano Medicines & Nano Probes Research Group, University of Tours, Department of Rheumatology, CHRU de Tours, Tours, France.; Rheumatology Department, Centre Hospitalier du Mans, Le Mans, France.; Department of Infectious Diseases, Tourcoing Hospital, Tourcoing, France.; Rheumatology Department, AP-HP, Hôpitaux Universitaires Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Centre of Immunology of Viral Infections and Autoimmune Diseases (IMVA), Inserm U1184, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.; Montalembert Medical Center, Clermond-Frerrand, France.; Multidisciplinary Health Center of Conlie, Conlie, France.; Rheumatology Department, Hôpital Sud, CHU de Rennes, 35000 Rennes, France; Rennes University, Inserm, CHU de Rennes, Institut NUMECAN (Nutrition Metabolisms and Cancer), UMR 1317, 35000 Rennes, France.; Rheumatology Department, CHU d'Orléans, Orléans University, 45067 Orléans, France. Electronic address: [email protected].

DOI: 10.1016/j.jbspin.2023.105664

Link outs

Free resources

Medical:

https://medlineplus.gov/bursitis.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Olecranon Process, Bacterial Infections, Elbow Joint, Bursitis, Anti-Bacterial Agents